Small late stage (7-10 days post symptoms) study of nasal swab RNA with 12 control and 33 patients, showing no significant differences (significant reduction in viral load is seen in both groups).
The groups are not comparable, with significant differences seen between hospitalized and non-hospitalized patients. 9 of 10 hospitalized patients were in the HCQ group and only one in the control group. 2 additional control patients were added between the first and second version of this preprint (including the only hospitalized control patient).
Komissarov et al., 6/30/2020, retrospective, Russia, Asia, Europe, preprint, 8 authors.
risk of viral load, 25.0% higher, RR 1.25, p = 0.45, treatment 26, control 10.